Annals of Oncology 14:1783-1790, 2003
© 2003 European Society for Medical Oncology
Original Paper |
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863
1 University of California at San Francisco, San Francisco, CA; 2 University of Illinois, Chicago, IL; 3 CALGB Statistical Center, Durham, NC; 4 Roswell Park Cancer Institute, Buffalo, NY; 5 University of Iowa Hospitals, Iowa City, IA; 6 Walter Reed Army Medical Center, Bethesda, MD; 7 North Shore University Hospital, Manhasset, NY; 8 Ohio State University, Columbus, OH; 9 Georgetown University, Washington, DC; 10 University of Chicago, IL, USA
Received 5 February 2003; revised 30 July 2003; accepted 12 August 2003
Background:
To ascertain if hepatic or renal dysfunction or prior pelvic radiation (XRT) leads to increased toxicity at a given dose of irinotecan and to characterize the pharmacokinetics of irinotecan and its major metabolites in patients with hepatic or renal dysfunction.
Patients and methods:
Adults with tumors appropriate for irinotecan therapy and who had abnormal liver or renal function tests or had prior radiation to the pelvis were eligible. Patients were assigned to one of four treatment cohorts: I, aspartate aminotransferase (AST) 
3x upper limit of normal and direct bilirubin <1.0 mg/dl; II, direct bilirubin 1.0–7.0 mg/dl; III, creatinine 1.6–5.0 mg/dl with normal liver function; IV, prior pelvic XRT with normal liver and renal function. Starting with reduced doses of either 145 or 225 mg/m2, irinotecan was administered every 3 weeks to at least three patients within each cohort. Irinotecan and its metabolites in the blood were measured in all patients.
Results:
Thirty-five patients were evaluable for toxicity. No dose-limiting toxicity was seen in cohort I, although only three patients were treated and at a dose of 225 mg/m2. Patients with elevations of direct bilirubin had dose-limiting toxicities, even though the starting dose was 145 mg/m2. These same patients appeared to have comparable exposure to the active metabolite SN-38 as normal patients treated with full-dose irinotecan. Patients with elevations of creatinine or with prior pelvic radiotherapy did not appear to have increased risk of toxicity at the doses explored in this study.
Conclusions:
Patients with elevated bilirubin treated with irinotecan have an increased risk of toxicity and a dose reduction is recommended. Patients with elevated AST, creatinine or prior pelvic radiation do not appear to have increased sensitivity to irinotecan, but the data are not adequate to support a specific dosing recommendation.
Key words: hepatic dysfunction, irinotecan, pharmacokinetics
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. A. Miller, D. J. Murry, K. Owzar, D. R. Hollis, E. B. Kennedy, G. Abou-Alfa, A. Desai, J. Hwang, M. A. Villalona-Calero, E. C. Dees, et al. Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 J. Clin. Oncol., April 10, 2009; 27(11): 1800 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Czock, F. M. Rasche, B. Boesler, M. Shipkova, and F. Keller Irinotecan in Cancer Patients with End-Stage Renal Failure Ann. Pharmacother., February 1, 2009; 43(2): 363 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Kohne, G. Folprecht, R. M. Goldberg, E. Mitry, and P. Rougier Chemotherapy in Elderly Patients with Colorectal Cancer Oncologist, April 1, 2008; 13(4): 390 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lichtman Pharmacology of Antineoplastic Agents for Older Patients ASCO Educational Book, January 1, 2008; 2008(1): 210 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Superfin, A. A. Iannucci, and A. M. Davies Commentary: Oncologic Drugs in Patients with Organ Dysfunction: A Summary Oncologist, September 1, 2007; 12(9): 1070 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Miller, D. J. Murry, K. Owzar, D. R. Hollis, L. D. Lewis, H. L. Kindler, J. L. Marshall, M. A. Villalona-Calero, M. J. Edelman, R. J. Hohl, et al. Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101 J. Clin. Oncol., July 20, 2007; 25(21): 3055 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujiwara, I. Sekine, Y. Ohe, H. Kunitoh, N. Yamamoto, H. Nokihara, Y. Simmyo, T. Fukui, K. Yamada, and T. Tamura Serum Total Bilirubin as a Predictive Factor for Severe Neutropenia in Lung Cancer Patients Treated with Cisplatin and Irinotecan Jpn. J. Clin. Oncol., May 30, 2007; (2007) hym033v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Schaaf, L. A. Hammond, S. J. Tipping, R. M. Goldberg, R. Goel, J. G. Kuhn, L. L. Miller, L. D. Compton, L. A. Cisar, G. L. Elfring, et al. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clin. Cancer Res., June 15, 2006; 12(12): 3782 - 3791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ratain, A. A. Miller, H. L. McLeod, A. P. Venook, M. J. Egorin, and R. L. Schilsky The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin. Cancer Res., June 1, 2006; 12(11): 3612s - 3616s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lichtman, D. Hollis, A. A. Miller, G. L. Rosner, C. A. Rhoades, E. P. Lester, F. Millard, J. Byrd, S. A. Cullinan, D. M. Rosen, et al. Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762) J. Clin. Oncol., April 20, 2006; 24(12): 1846 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wasil and S. M. Lichtman Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly Oncologist, September 1, 2005; 10(8): 602 - 612. [Abstract] [Full Text] [PDF]
|
|